fig2
![Gemcitabine followed by radiotherapy in treatment of newly diagnosed high-grade gliomas](https://image.oaes.cc/e0539f65-3cbb-40c5-a875-5d8f87d3d926/1387.fig.2.png)
Figure 2. (a) PFS at a follow up of 18 months. The median PFS was 7.9 months (95% CI 6.1-9.7); (b) analysis of OS for 18 months, median OS was 11.8 months (95% CI 10.0-13.6). PFS: progression free survival; OS: overall survival
Figure 2. (a) PFS at a follow up of 18 months. The median PFS was 7.9 months (95% CI 6.1-9.7); (b) analysis of OS for 18 months, median OS was 11.8 months (95% CI 10.0-13.6). PFS: progression free survival; OS: overall survival
All published articles are preserved here permanently:
https://www.portico.org/publishers/oae/